NASDAQ:ALEC Alector Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alector Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.18 -0.04 (-0.36 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$10.75Now: $11.18▼$11.6450-Day Range$11.22MA: $13.25▼$15.1652-Week Range$10.75Now: $11.18▼$35.93Volume800,001 shsAverage Volume719,263 shsMarket Capitalization$886.15 millionP/E RatioN/ADividend YieldN/ABeta0.41 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.80, Alector has a forecasted upside of 193.4% from its current price of $11.18.Amount of Analyst CoverageAlector has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAlector has received 119 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlector has received 124 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlector has received 51.03% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote “Outperform” if you believe ALEC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $229,600.00 in company stock.Percentage Held by InsidersOnly 13.90% of the stock of Alector is held by insiders.Percentage Held by Institutions62.99% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to decrease in the coming year, from ($2.24) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALEC Previous Symbol CUSIPN/A CIKN/A Webwww.alector.com Phone415-231-5660Debt Debt-to-Equity RatioN/A Current Ratio7.75 Quick Ratio7.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.22 million Price / Sales41.76 Cash FlowN/A Price / Cash FlowN/A Book Value$2.83 per share Price / Book3.95Profitability EPS (Most Recent Fiscal Year)($1.71) Net Income$-105,390,000.00 Net Margins-775.34% Return on Equity-50.88% Return on Assets-28.63%Miscellaneous Employees91 Outstanding Shares79,262,000Market Cap$886.15 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $11.18 -0.04 (-0.36 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ALEC News and Ratings via Email Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Alector (NASDAQ:ALEC) Frequently Asked Questions How has Alector's stock price been impacted by Coronavirus (COVID-19)? Alector's stock was trading at $24.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALEC shares have decreased by 55.1% and is now trading at $11.18. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Alector? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alector. When is Alector's next earnings date? Alector is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Alector. How were Alector's earnings last quarter? Alector Inc (NASDAQ:ALEC) issued its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.09. The firm had revenue of $3.17 million for the quarter, compared to analysts' expectations of $8.84 million. Alector had a negative net margin of 775.34% and a negative return on equity of 50.88%. View Alector's earnings history. What price target have analysts set for ALEC? 8 brokerages have issued 1 year price targets for Alector's shares. Their forecasts range from $28.00 to $41.00. On average, they anticipate Alector's stock price to reach $32.80 in the next year. This suggests a possible upside of 193.4% from the stock's current price. View analysts' price targets for Alector. Are investors shorting Alector? Alector saw a increase in short interest in August. As of August 14th, there was short interest totaling 8,750,000 shares, an increase of 20.9% from the July 30th total of 7,240,000 shares. Based on an average daily volume of 895,600 shares, the days-to-cover ratio is currently 9.8 days. Currently, 16.7% of the shares of the company are sold short. View Alector's Short Interest. Who are some of Alector's key competitors? Some companies that are related to Alector include Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Immunovant (IMVT), Twist Bioscience (TWST), Legend Biotech (PCVX), Kodiak Sciences (KOD), Sorrento Therapeutics (SRNE), Revolution Medicines (RVMD), Mesoblast (MESO), SpringWorks Therapeutics (SWTX), BAVARIAN NORDIC/S (BVNRY), Editas Medicine (EDIT), Forma Therapeutics (FMTX), NanoString Technologies (NSTG) and Cortexyme (CRTX). View all competitors. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), Pfizer (PFE), QUALCOMM (QCOM), Kaleido Biosciences (KLDO), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Intel (INTC) and Crispr Therapeutics (CRSP). Who are Alector's key executives? Alector's management team includes the following people: Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)Dr. Robert S. King, Chief Devel. Officer (Age 56)Dr. Asa Abeliovich M.D., Ph.D., Co-Founder When did Alector IPO? (ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO. What is Alector's stock symbol? Alector trades on the NASDAQ under the ticker symbol "ALEC." Who are Alector's major shareholders? Alector's stock is owned by many different retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (7.54%), Vanguard Group Inc. (6.14%), Federated Hermes Inc. (5.40%), FMR LLC (4.39%), Gilder Gagnon Howe & Co. LLC (3.24%) and Deerfield Management Company L.P. Series C (2.12%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire. View institutional ownership trends for Alector. Which major investors are selling Alector stock? ALEC stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Marshall Wace North America L.P., Gilder Gagnon Howe & Co. LLC, Federated Hermes Inc., FMR LLC, Deerfield Management Company L.P. Series C, Holocene Advisors LP, and Artal Group S.A.. Company insiders that have sold Alector company stock in the last year include Calvin Yu, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney, and Terrance Mcguire. View insider buying and selling activity for Alector. Which major investors are buying Alector stock? ALEC stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Vanguard Group Inc., Point72 Asset Management L.P., Man Group plc, Swiss National Bank, Marshall Wace LLP, Nuveen Asset Management LLC, and First Trust Advisors LP. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc. View insider buying and selling activity for Alector. How do I buy shares of Alector? Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Alector's stock price today? One share of ALEC stock can currently be purchased for approximately $11.18. How big of a company is Alector? Alector has a market capitalization of $886.15 million and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe. What is Alector's official website? The official website for Alector is www.alector.com. How can I contact Alector? Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
